Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Efficacy was evaluated in Study CK-301-101 (ClinicalTrials.gov. Identifier: NCT03212404), a multicenter,